<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03312023</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00074723</org_study_id>
    <nct_id>NCT03312023</nct_id>
  </id_info>
  <brief_title>Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection</brief_title>
  <acronym>APOSTLE</acronym>
  <official_title>A Phase II Open-Label Study of Ledipasvir/Sofosbuvir for 12 Weeks in Subjects With Hepatitis B Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of therapy against chronic hepatitis B are to decrease the morbidity and mortality&#xD;
      related to chronic HBV infection. Currently available antiviral therapy can suppress viral&#xD;
      replication but only a small proportion attain functional cure, which is defined as HBV&#xD;
      surface antigen-to-antibody seroconversion. Hepatitis B surface antigen (HBsAg) is a marker&#xD;
      of persistent hepatitis B infection.&#xD;
&#xD;
      It has been observed that patients who had both hepatitis B and hepatitis C, and who were&#xD;
      treated for their hepatitis C with 12 weeks of ledipasvir/sofosbuvir for had a decline in&#xD;
      HBsAg levels. This study hypothesizes that a similar decrease would be seen in mono-infected&#xD;
      hepatitis B subjects over the course of 12 weeks treatment with ledipasvir/sofosbuvir.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">August 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label Study, multi-arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Ten potential subjects for Groups C and D will be randomized in a 1:1 fashion.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Serum Hepatitis B Surface Antigen (HBsAg as Measured in log10 IU/mL) Level as an Indicator of Antiviral Activity of Ledipasvir and/or Sofosbuvir in Subjects With Chronic Hepatitis B From Baseline to End of 12 Weeks Treatment.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Subjects with chronic hepatitis B will be give 12 weeks of ledipasvir and/or sofosbuvir and their HBsAg will be measured at baseline, on each visits during therapy, and at end of therapy (week 12). The change (decline) in HBsAg from baseline to end of the 12 week treatment will be compared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Ledipasvir and/or Sofosbuvir Treatment in Subjects With Chronic Hepatitis B Infection.</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Number of subjects who discontinued study drug due to adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum Hepatitis B Virus DNA Levels (HBV DNA as Measured in IU/mL) With Treatment of Ledipasvir and/or Sofosbuvir From Baseline to End of 12 Weeks of Treatment in Subjects With Chronic Hepatitis B Infection.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Subjects with chronic hepatitis B will be give 12 weeks of ledipasvir and/or sofosbuvir and their serum hepatitis B DNA levels (HBV DNA) will be measured at baseline, on each visits during therapy, and at end of therapy (week 12). The change in HBV DNA levels from baseline to end of the 12 week treatment will be compared.&#xD;
Note: Group B (virally suppressed HBV subjects) - all had HBV DNA below the limit of detection; Hence, mean change was 0.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Group A (LDV/SOF for low replicative HBV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B in low replicative state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (LDV/SOF for viral suppressed HBV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B, virally suppressed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (SOF for low replicative HBV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks treatment with sofosbuvir (Sovaldi) for chronic hepatitis B in low replicative state.&#xD;
Randomized 1:1 with Group D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D (LDV for low replicative HBV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks treatment with ledipasvir for chronic hepatitis B in low replicative state.&#xD;
Randomized 1:1 with Group C.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]</intervention_name>
    <description>1 pill once daily for 12 weeks for Group A</description>
    <arm_group_label>Group A (LDV/SOF for low replicative HBV)</arm_group_label>
    <arm_group_label>Group B (LDV/SOF for viral suppressed HBV)</arm_group_label>
    <other_name>Harvoni</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir 400 MG [Sovaldi]</intervention_name>
    <description>1 pill once daily for 12 weeks for Group C</description>
    <arm_group_label>Group C (SOF for low replicative HBV)</arm_group_label>
    <other_name>GS-7977</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ledipasvir 90 MG</intervention_name>
    <description>1 pill once daily for 12 weeks for Group D</description>
    <arm_group_label>Group D (LDV for low replicative HBV)</arm_group_label>
    <other_name>GS-5885</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
        Participants in Groups A, C &amp; D (Chronic HBV, low replicative state not requiring&#xD;
        treatment):&#xD;
&#xD;
          1. Provision of signed and dated informed consent form&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Male or female, aged 18 or older at screening&#xD;
&#xD;
          4. Diagnosed with chronic hepatitis B infection defined as one of the following:&#xD;
&#xD;
               1. HBsAg or HBV DNA positivity for at least 6 months&#xD;
&#xD;
               2. Medical records indicating a chronic HBV infection&#xD;
&#xD;
          5. HBeAg negative at screening&#xD;
&#xD;
          6. HBV DNA &gt; lower level of quantitation (LLOQ)&#xD;
&#xD;
          7. Quantitative HBsAg at least 10 IU/mL at screening&#xD;
&#xD;
          8. Ability to take oral medication and be willing to adhere to the twelve week study drug&#xD;
             regimen&#xD;
&#xD;
          9. For females of reproductive potential: usual practice of complete abstinence from&#xD;
             sexual intercourse with a member of the opposite sex OR use of at least one form of&#xD;
             highly effective contraception for at least 1 month prior to enrollment and agreement&#xD;
             to use such a method during study participation and for an additional 30 days after&#xD;
             the end of study drug administration&#xD;
&#xD;
         10. For males of reproductive potential: usual practice of complete abstinence from sexual&#xD;
             intercourse with a member of the opposite sex OR use of at least one form of highly&#xD;
             effective contraception for at least 1 month prior to enrollment and agreement to use&#xD;
             such a method during study participation and for an additional 14 days after the end&#xD;
             of study drug administration&#xD;
&#xD;
         11. Ability to communicate effectively with the study investigator and key staff&#xD;
&#xD;
         12. Medical management provided by a primary care provider&#xD;
&#xD;
         13. Ability to store medications at a room temperature of less than 86 degrees Fahrenheit&#xD;
&#xD;
         14. Not on antiviral therapy or requiring treatment for HBV during screening&#xD;
&#xD;
        Participants in Group B (Chronic HBV, virally suppressed):&#xD;
&#xD;
          1. Provision of signed and dated informed consent form&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Male or female, aged 18 or older at screening&#xD;
&#xD;
          4. Diagnosed with chronic hepatitis B infection defined as one of the following:&#xD;
&#xD;
               1. HBsAg or HBV DNA positivity for at least 6 months&#xD;
&#xD;
               2. Medical records indicating a chronic HBV infection&#xD;
&#xD;
          5. Receiving oral anti-HBV medications (either tenofovir alafenamide, tenofovir&#xD;
             disoproxil fumarate, entecavir, or a combination of no more than 2 of these agents)&#xD;
             for at least three months prior to enrollment&#xD;
&#xD;
          6. HBV DNA ˂ lower level of quantitation (LLOQ) at screening and for at least three&#xD;
             months prior&#xD;
&#xD;
          7. Quantitative HBsAg at least 10 IU/mL at screening&#xD;
&#xD;
          8. Ability to take oral medication and be willing to adhere to the twelve week study drug&#xD;
             regimen&#xD;
&#xD;
          9. For females of reproductive potential: usual practice of complete abstinence from&#xD;
             sexual intercourse with a member of the opposite sex OR use of at least one form of&#xD;
             highly effective contraception for at least 1 month prior to enrollment and agreement&#xD;
             to use such a method during study participation and for an additional 30 days after&#xD;
             the end of study drug administration&#xD;
&#xD;
         10. For males of reproductive potential: usual practice of complete abstinence from sexual&#xD;
             intercourse with a member of the opposite sex OR use of at least one form of highly&#xD;
             effective contraception for at least 1 month prior to enrollment and agreement to use&#xD;
             such a method during study participation and for an additional 14 days after the end&#xD;
             of study drug administration&#xD;
&#xD;
         11. Ability to communicate effectively with the study investigator and key staff&#xD;
&#xD;
         12. Medical management provided by a primary care provider&#xD;
&#xD;
         13. Ability to store medications at a room temperature of less than 86 degrees Fahrenheit&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          1. Coinfection with hepatitis C, hepatitis D or human immunodeficiency virus (HIV)&#xD;
&#xD;
          2. Pregnancy or lactation&#xD;
&#xD;
          3. Known allergic reactions to sofosbuvir or ledipasvir&#xD;
&#xD;
          4. Treatment with another investigational drug or other intervention within three months&#xD;
&#xD;
          5. Evidence of cirrhosis or hepatic decompensation such as:&#xD;
&#xD;
               -  Platelets less than 100,000 /mm3&#xD;
&#xD;
               -  Albumin less than 3.5 g/dL&#xD;
&#xD;
               -  INR greater than 1.7 or Prothrombin time of 1.5 times the upper limit of normal&#xD;
                  (ULN)&#xD;
&#xD;
               -  Total bilirubin of 1.5 times the upper limit of normal&#xD;
&#xD;
               -  FibroTest (or FibroSure®) of 0.75 or greater&#xD;
&#xD;
          6. Abnormal hematological and biochemical parameters at screening including:&#xD;
&#xD;
               -  White blood cell count less than 2500 cells/uL&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) less than 1,000 cells/mm3 (less than 750 mm3 for&#xD;
                  African or African-American subjects)&#xD;
&#xD;
               -  Hemoglobin less than 12 g/dL for males, less than 11 g/dL for females&#xD;
&#xD;
               -  AST or ALT of two times the upper limit of normal&#xD;
&#xD;
               -  Estimated GFR less than 50 mL/min&#xD;
&#xD;
               -  Glycosylated hemoglobin (HbA1c) greater than 8.5%&#xD;
&#xD;
          7. Current or prior history of any of the following:&#xD;
&#xD;
               -  Immunodeficiency disorders or autoimmune disease (e.g. Systemic lupus&#xD;
                  erythematosus, rheumatoid arthritis, inflammatory bowel diseases, sarcoidosis,&#xD;
                  psoriasis of greater than mild severity)&#xD;
&#xD;
               -  Severe pulmonary disorders, significant cardiac diseases&#xD;
&#xD;
               -  Gastrointestinal disorder with post-operative condition that could interfere with&#xD;
                  the absorption of the study drugs&#xD;
&#xD;
               -  Significant psychiatric illness that in the judgment of the Investigator, is a&#xD;
                  contraindication to protocol participation or impairs a volunteer's ability to&#xD;
                  give informed consent&#xD;
&#xD;
               -  Any malignancy diagnosed within 5 years (not including recent localized treatment&#xD;
                  of squamous or non-invasive basal cell skin cancer; cervical carcinoma in situ&#xD;
                  appropriately treated prior to screening)&#xD;
&#xD;
               -  Solid organ transplantation&#xD;
&#xD;
               -  Poor venous access&#xD;
&#xD;
          8. Screening ECG with clinically significant findings&#xD;
&#xD;
          9. Evidence of HCC (e.g., α fetoprotein &gt; 50ng/mL or radiologic evidence)&#xD;
&#xD;
         10. Clinically significant illicit drug or alcohol abuse within 12 months of screening.&#xD;
             Subjects on methadone maintenance treatment or prescribed opioid may be included.&#xD;
&#xD;
         11. Use of amiodarone within 90 days of enrollment; or carbamazepine, phenytoin,&#xD;
             phenobarbital, oxcarbazepine, rifabutin, rifampin, rifapentine, St. John's wort,&#xD;
             rosuvastatin, or interferon within 30 days of enrollment or expected use of these&#xD;
             prohibited drugs during study participation. Use of or expected need of proton-pump&#xD;
             inhibitors more than 20 mg omeprazole equivalent or H2 receptor antagonist more than&#xD;
             40 mg famotidine BID equivalent within 7 days of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel V Chua, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Human Virology (IHV), University of Maryland Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 29, 2017</study_first_submitted>
  <study_first_submitted_qc>October 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2017</study_first_posted>
  <results_first_submitted>July 12, 2021</results_first_submitted>
  <results_first_submitted_qc>August 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 25, 2021</results_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Joel Chua</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>HBsAg</keyword>
  <keyword>Ledipasvir/Sofosbuvir</keyword>
  <keyword>Hepatitis B treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Herpesviridae Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 18, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT03312023/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A (LDV/SOF for Low Replicative HBV)</title>
          <description>12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B in low replicative state.&#xD;
Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]: 1 pill once daily for 12 weeks for Group A</description>
        </group>
        <group group_id="P2">
          <title>Group B (LDV/SOF for Viral Suppressed HBV)</title>
          <description>12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B, virally suppressed.&#xD;
Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]: 1 pill once daily for 12 weeks for Group A</description>
        </group>
        <group group_id="P3">
          <title>Group C (SOF for Low Replicative HBV)</title>
          <description>12 weeks treatment with sofosbuvir (Sovaldi) for chronic hepatitis B in low replicative state.&#xD;
Randomized 1:1 with Group D.&#xD;
Sofosbuvir 400 MG [Sovaldi]: 1 pill once daily for 12 weeks for Group C</description>
        </group>
        <group group_id="P4">
          <title>Group D (LDV for Low Replicative HBV)</title>
          <description>12 weeks treatment with ledipasvir for chronic hepatitis B in low replicative state.&#xD;
Randomized 1:1 with Group C.&#xD;
Ledipasvir 90 MG: 1 pill once daily for 12 weeks for Group D</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Week 12</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A (LDV/SOF for Low Replicative HBV)</title>
          <description>12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B in low replicative state.&#xD;
Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]: 1 pill once daily for 12 weeks for Group A</description>
        </group>
        <group group_id="B2">
          <title>Group B (LDV/SOF for Viral Suppressed HBV)</title>
          <description>12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B, virally suppressed.&#xD;
Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]: 1 pill once daily for 12 weeks for Group A</description>
        </group>
        <group group_id="B3">
          <title>Group C (SOF for Low Replicative HBV)</title>
          <description>12 weeks treatment with sofosbuvir (Sovaldi) for chronic hepatitis B in low replicative state.&#xD;
Randomized 1:1 with Group D.&#xD;
Sofosbuvir 400 MG [Sovaldi]: 1 pill once daily for 12 weeks for Group C</description>
        </group>
        <group group_id="B4">
          <title>Group D (LDV for Low Replicative HBV)</title>
          <description>12 weeks treatment with ledipasvir for chronic hepatitis B in low replicative state.&#xD;
Randomized 1:1 with Group C.&#xD;
Ledipasvir 90 MG: 1 pill once daily for 12 weeks for Group D</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.3" lower_limit="30" upper_limit="73"/>
                    <measurement group_id="B2" value="57.6" lower_limit="42" upper_limit="73"/>
                    <measurement group_id="B3" value="43.5" lower_limit="38" upper_limit="57"/>
                    <measurement group_id="B4" value="52.3" lower_limit="42" upper_limit="61"/>
                    <measurement group_id="B5" value="50.0" lower_limit="30" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Negative eAg</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Normal ALT</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Serum Hepatitis B Surface Antigen (HBsAg as Measured in log10 IU/mL) Level as an Indicator of Antiviral Activity of Ledipasvir and/or Sofosbuvir in Subjects With Chronic Hepatitis B From Baseline to End of 12 Weeks Treatment.</title>
        <description>Subjects with chronic hepatitis B will be give 12 weeks of ledipasvir and/or sofosbuvir and their HBsAg will be measured at baseline, on each visits during therapy, and at end of therapy (week 12). The change (decline) in HBsAg from baseline to end of the 12 week treatment will be compared.</description>
        <time_frame>12 weeks</time_frame>
        <population>Intention to treat population - all subjects who have received at least one study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (LDV/SOF for Low Replicative HBV)</title>
            <description>12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B in low replicative state.&#xD;
Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]: 1 pill once daily for 12 weeks for Group A</description>
          </group>
          <group group_id="O2">
            <title>Group B (LDV/SOF for Viral Suppressed HBV)</title>
            <description>12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B, virally suppressed.&#xD;
Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]: 1 pill once daily for 12 weeks for Group A</description>
          </group>
          <group group_id="O3">
            <title>Group C (SOF for Low Replicative HBV)</title>
            <description>12 weeks treatment with sofosbuvir (Sovaldi) for chronic hepatitis B in low replicative state.&#xD;
Randomized 1:1 with Group D.&#xD;
Sofosbuvir 400 MG [Sovaldi]: 1 pill once daily for 12 weeks for Group C</description>
          </group>
          <group group_id="O4">
            <title>Group D (LDV for Low Replicative HBV)</title>
            <description>12 weeks treatment with ledipasvir for chronic hepatitis B in low replicative state.&#xD;
Randomized 1:1 with Group C.&#xD;
Ledipasvir 90 MG: 1 pill once daily for 12 weeks for Group D</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Serum Hepatitis B Surface Antigen (HBsAg as Measured in log10 IU/mL) Level as an Indicator of Antiviral Activity of Ledipasvir and/or Sofosbuvir in Subjects With Chronic Hepatitis B From Baseline to End of 12 Weeks Treatment.</title>
          <description>Subjects with chronic hepatitis B will be give 12 weeks of ledipasvir and/or sofosbuvir and their HBsAg will be measured at baseline, on each visits during therapy, and at end of therapy (week 12). The change (decline) in HBsAg from baseline to end of the 12 week treatment will be compared.</description>
          <population>Intention to treat population - all subjects who have received at least one study drug.</population>
          <units>Log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.2"/>
                    <measurement group_id="O2" value="0.40" spread="0.3"/>
                    <measurement group_id="O3" value="0.19" spread="0.3"/>
                    <measurement group_id="O4" value="-0.05" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events Leading to Permanent Discontinuation of Ledipasvir and/or Sofosbuvir Treatment in Subjects With Chronic Hepatitis B Infection.</title>
        <description>Number of subjects who discontinued study drug due to adverse event</description>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A (LDV/SOF for Low Replicative HBV)</title>
            <description>12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B in low replicative state.&#xD;
Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]: 1 pill once daily for 12 weeks for Group A</description>
          </group>
          <group group_id="O2">
            <title>Group B (LDV/SOF for Viral Suppressed HBV)</title>
            <description>12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B, virally suppressed.&#xD;
Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]: 1 pill once daily for 12 weeks for Group A</description>
          </group>
          <group group_id="O3">
            <title>Group C (SOF for Low Replicative HBV)</title>
            <description>12 weeks treatment with sofosbuvir (Sovaldi) for chronic hepatitis B in low replicative state.&#xD;
Randomized 1:1 with Group D.&#xD;
Sofosbuvir 400 MG [Sovaldi]: 1 pill once daily for 12 weeks for Group C</description>
          </group>
          <group group_id="O4">
            <title>Group D (LDV for Low Replicative HBV)</title>
            <description>12 weeks treatment with ledipasvir for chronic hepatitis B in low replicative state.&#xD;
Randomized 1:1 with Group C.&#xD;
Ledipasvir 90 MG: 1 pill once daily for 12 weeks for Group D</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events Leading to Permanent Discontinuation of Ledipasvir and/or Sofosbuvir Treatment in Subjects With Chronic Hepatitis B Infection.</title>
          <description>Number of subjects who discontinued study drug due to adverse event</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Serum Hepatitis B Virus DNA Levels (HBV DNA as Measured in IU/mL) With Treatment of Ledipasvir and/or Sofosbuvir From Baseline to End of 12 Weeks of Treatment in Subjects With Chronic Hepatitis B Infection.</title>
        <description>Subjects with chronic hepatitis B will be give 12 weeks of ledipasvir and/or sofosbuvir and their serum hepatitis B DNA levels (HBV DNA) will be measured at baseline, on each visits during therapy, and at end of therapy (week 12). The change in HBV DNA levels from baseline to end of the 12 week treatment will be compared.&#xD;
Note: Group B (virally suppressed HBV subjects) - all had HBV DNA below the limit of detection; Hence, mean change was 0.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A (LDV/SOF for Low Replicative HBV)</title>
            <description>12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B in low replicative state.&#xD;
Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]: 1 pill once daily for 12 weeks for Group A</description>
          </group>
          <group group_id="O2">
            <title>Group B (LDV/SOF for Virally Suppressed HBV)</title>
            <description>12 weeks of treatment with ledipasvir/sofosbuvir (Harvoni) for chronical hepatitis B virally suppressed on HBV meds</description>
          </group>
          <group group_id="O3">
            <title>Group C (SOF for Low Replicative HBV)</title>
            <description>12 weeks treatment with sofosbuvir (Sovaldi) for chronic hepatitis B in low replicative state.&#xD;
Randomized 1:1 with Group D.&#xD;
Sofosbuvir 400 MG [Sovaldi]: 1 pill once daily for 12 weeks for Group C</description>
          </group>
          <group group_id="O4">
            <title>Group D (LDV for Low Replicative HBV)</title>
            <description>12 weeks treatment with ledipasvir for chronic hepatitis B in low replicative state.&#xD;
Randomized 1:1 with Group C.&#xD;
Ledipasvir 90 MG: 1 pill once daily for 12 weeks for Group D</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum Hepatitis B Virus DNA Levels (HBV DNA as Measured in IU/mL) With Treatment of Ledipasvir and/or Sofosbuvir From Baseline to End of 12 Weeks of Treatment in Subjects With Chronic Hepatitis B Infection.</title>
          <description>Subjects with chronic hepatitis B will be give 12 weeks of ledipasvir and/or sofosbuvir and their serum hepatitis B DNA levels (HBV DNA) will be measured at baseline, on each visits during therapy, and at end of therapy (week 12). The change in HBV DNA levels from baseline to end of the 12 week treatment will be compared.&#xD;
Note: Group B (virally suppressed HBV subjects) - all had HBV DNA below the limit of detection; Hence, mean change was 0.</description>
          <units>Log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.6"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0.68" spread="0.4"/>
                    <measurement group_id="O4" value="0.21" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A (LDV/SOF for Low Replicative HBV)</title>
          <description>12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B in low replicative state.&#xD;
Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]: 1 pill once daily for 12 weeks for Group A</description>
        </group>
        <group group_id="E2">
          <title>Group B (LDV/SOF for Viral Suppressed HBV)</title>
          <description>12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B, virally suppressed.&#xD;
Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]: 1 pill once daily for 12 weeks for Group A</description>
        </group>
        <group group_id="E3">
          <title>Group C (SOF for Low Replicative HBV)</title>
          <description>12 weeks treatment with sofosbuvir (Sovaldi) for chronic hepatitis B in low replicative state.&#xD;
Randomized 1:1 with Group D.&#xD;
Sofosbuvir 400 MG [Sovaldi]: 1 pill once daily for 12 weeks for Group C</description>
        </group>
        <group group_id="E4">
          <title>Group D (LDV for Low Replicative HBV)</title>
          <description>12 weeks treatment with ledipasvir for chronic hepatitis B in low replicative state.&#xD;
Randomized 1:1 with Group C.&#xD;
Ledipasvir 90 MG: 1 pill once daily for 12 weeks for Group D</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Edema, peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rhinitis, allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash, maculopapular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joel V. Chua</name_or_title>
      <organization>Institute of Human Virology, University of Maryland Baltimore</organization>
      <phone>1-410-706-5704</phone>
      <email>jchua@ihv.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

